| CD38单克隆抗体治疗复发难治多发性骨髓瘤的疗效 |
| |
| 引用本文： | 张丹丹,王华. CD38单克隆抗体治疗复发难治多发性骨髓瘤的疗效[J]. 滨州医学院学报, 2021, 44(2): 157-160. DOI: 10.19739/j.cnki.issn1001-9510.2021.02.019 |
| |
| 作者姓名： | 张丹丹 王华 |
| |
| 作者单位： | 滨州医学院第二临床医学院 山东 烟台 264003 |
| |
| 摘 要： | 近年来,蛋白酶体抑制剂(PIs)、免疫调节药物(IMiDs)纳入到多发性骨髓瘤(MM)的治疗标准中,改善了MM患者的预后,但MM仍然无法治愈,所有患者最终都会复发。CD38单克隆抗体对复发/难治MM(RRMM)显示出一定的临床疗效,本文将对CD38单克隆抗体的作用机制及两种CD38单克隆抗体isatuximab和daratuumab治疗RRMM的进展进行综述。
|
| 关 键 词： | MM 复发/难治 CD38单克隆抗体 daratumumab isatuximab |
| 收稿时间： | 2020-11-13 |
Efficacy of CD38 monoclonal antibody in the treatment of relapsed refractory multiple myeloma |
| |
| ZHANG Dandan,WANG Hua. Efficacy of CD38 monoclonal antibody in the treatment of relapsed refractory multiple myeloma[J]. Journal of Binzhou Medical College, 2021, 44(2): 157-160. DOI: 10.19739/j.cnki.issn1001-9510.2021.02.019 |
| |
| Authors: | ZHANG Dandan WANG Hua |
| |
| Affiliation: | The Second Clinical Medical College, Binzhou Medical University, Yantai 264003, Shandong, P. R. China |
| |
| Abstract: | The incorporation of proteasome inhibitors and immunomodulatory drugs into the standard of treatment has improved outcomes in patients with multiple myeloma over the years, but MM is still incurable, and all patients will eventually relapse. CD38 monoclonal antibody has shown certain clinical efficacy in the treatment of relapsing refractory multiple myeloma. This article will review the mechanism of action of CD38 monoclonal antibody, and review the progress of two kinds of CD38 monoclonal antibodies, isatuximab and daratuumab, in the treatment of RRMM. |
| |
| Keywords: | multiple myeloma relapsed/refractory CD38 monoclonal antibody daratumumab isatuximab |
| 本文献已被 万方数据 等数据库收录！ |
| 点击此处可从《滨州医学院学报》浏览原始摘要信息 |
|
点击此处可从《滨州医学院学报》下载全文 |
|
